Relapses after Withdrawal of Proguanil Treatment in Tropical Splenomegaly Syndrome

David-West, Aba. S.
August 1974
British Medical Journal;8/24/1974, Vol. 3 Issue 5929, p499
Academic Journal
No abstract available.


Related Articles

  • Obscure splenomegaly in the tropics that is not the tropical splenomegaly syndrome. DeCock, Kevin M.; Lucas, S.B.; Rees, P.H.; Hodgen, A.N.; Jupp, R.A.; Slavin, B. // British Medical Journal (Clinical Research Edition);11/5/1983, Vol. 287 Issue 6402, p1347 

    Examines the undiagnosed tropical splenomegaly syndrome in patients. Criteria for the diagnosis; Analysis on the etiological relevance of malaria; Difficulty in the diagnosis of tropical splenomegaly syndrome by exclusion.

  • Serious Adverse Events During Ruxolitinib Treatment Discontinuation in Patients With Myelofibrosis. Tefferi, Ayalew; Pardanani, Animesh // Mayo Clinic Proceedings;Dec2011, Vol. 86 Issue 12, p1188 

    Ruxolitinib (INCB018424) is a JAK1 and JAK2 inhibitor recently evaluated for the treatment of myelofibrosis (MF) in early- and advanced-phase clinical trials. In 2 recent communications that focused on short-term and long-term ruxolitinib treatment outcome, respectively, the drug was shown to be...

  • Hyper-reactive malarial splenomegaly: therapeutic overview in Lahj Governorate, Yemen. Alwan, Saeed Mohamed; Abdullah, Hael Saeed; Humam, Mohsen Awadh Ben; Taresh, Abdul Samad // Middle East Journal of Family Medicine;May2012, Vol. 10 Issue 4, p33 

    Background: The three study areas are known as famous endemic areas of malaria, shistosomiasis and other tropical diseases in Lahj governorate. The study aimed to assess the response of proguanil HCl in patients with massive splenomegaly of different causes and to identify the HMS. Methods: A...

  • Treatment of Refractory Babesia microti Infection with Atovaquone-Proguanil in an HIV-Infected Patient: Case Report. Vyas, Jatin M.; Telford, Sam R.; Robbins, Gregory K. // Clinical Infectious Diseases;12/15/2007, Vol. 45 Issue 12, p1588 

    A patient with acquired immune deficiency syndrome presented with babesiosis 6 months after presumed tick exposure. Despite initial treatment with azithromycin and atovaquone, followed by quinine and clindamycin, he experienced an increasing parasite load. Finally, red blood cell exchange...

  • Cerebral Vein Thrombosis and Lupus Anticoagulant Antibodies. Marietta, Marco; Bertesi, Marcello; Simoni, Luisa; Castelli, Ilaria; Cappi, Cinzia; Torelli, Giuseppe // Clinical & Applied Thrombosis/Hemostasis;Jul2001, Vol. 7 Issue 3, p238 

    A letter to the editor is presented regarding a case of an atypical relapse of venous thromboembolism after withdrawal of oral anticoagulant therapy in a young woman carrying an antiphospholipid antibodies syndrome.

  • Natalizumab withdrawal.  // Reactions Weekly;10/17/2009, Issue 1274, p30 

    The article describes the cases of seven patients who experienced central nervous system (CNS) immune reconstitution syndrome after the withdrawal of natalizumab. The six patients were reported to have relapsing multiple sclerosis. It notes that treatment with intravenous (IV) steroids led to...

  • Alcohol Dependence, Withdrawal, and Relapse. Becker, Howard C. // Alcohol Research & Health;2008, Vol. 31 Issue 4, p348 

    Continued excessive alcohol consumption can lead to the development of dependence that is associated with a withdrawal syndrome when alcohol consumption is ceased or substantially reduced. This syndrome comprises physical signs as well as psychological symptoms that contribute to distress and...

  • Atypical case of alcohol-induced Cushingoid syndrome. Jenkins, R.M.; Page, M.McB. // British Medical Journal (Clinical Research Edition);4/4/1981, Vol. 282 Issue 6270, p1117 

    Presents a case on pituitary-dependent Cushing syndrome in alcoholics. Evidence of hypercorticosteroidism after alcohol withdrawal; Response to metyrapone with no relapse; Consideration of alcohol abuse in Cushing syndrome diagnosis.

  • Azacytidine treatment after discontinuation of immunosuppressants in patients with myelodysplastic syndrome and relapse after allo-SCT at a single center. Kim, S.-Y.; Cho, S.-G.; Cho, B.-S.; Kim, M.-S.; Eom, K.-S.; Kim, Y.-J.; Kim, H.-J.; Lee, S.; Min, C.-K.; Kim, D.-W.; Lee, J.-W.; Min, W.-S. // Bone Marrow Transplantation;Aug2010, Vol. 45 Issue 8, p1375 

    A letter to the editor is presented on azacytidine treatment for myelodysplastic syndrome (MDS) patients who ended immunosuppressants intake after relapse diagnosis.

  • Management of withdrawal syndromes and relapse prevention in drug and alcohol dependence. Miller, Norman S.; Gold, Mark S. // American Family Physician;7/1/1998, Vol. 58 Issue 1, p139 

    Discusses the management of patients undergoing treatment and recovery from alcohol and drug abuse disorders. Effectiveness of the medication benzodiazepines for withdrawal syndromes; Impact of participating in psychosocial methods of addiction treatment; Information on medication for relapse...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics